Schizophrenia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Schizophrenia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, as well as the Schizophrenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Schizophrenia Market by downloading the comprehensive report from DelveInsight @ Schizophrenia Therapeutics Market

 

Key Takeaways from the Schizophrenia Market Report

• In August 2024:- CF Pharma LLC– An Open Non-comparative Clinical Trial of the Pharmacokinetics, Safety and Tolerability of VLT-015, Tablets, 100 mg (Valentech LLC) With Single and Multiple Use in Patients With Schizophrenia. 15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.
• In August 2024:- Karuna Therapeutics:– A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia. The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
• The Schizophrenia Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• As per DelveInsight analysis, in 2023 the total diagnosed prevalent cases of schizophrenia in the 7MM were found to be approximately 3.8 million cases out of which the US accounted for nearly 1.4 million cases. It is anticipated that these numbers will rise by 2034 owning to advancements in psychiatric research and diagnostic criteria, potentially resulting in a more precise identification and diagnosis of schizophrenia on a global scale.
• Among the 7MM in the year 2023, EU4 and the UK accounted for nearly 42% of the total diagnosed prevalent cases of schizophrenia.
• DelveInsight’s analysis suggests that males have a higher susceptibility to schizophrenia, influenced by genetic, hormonal, and neurodevelopmental factors. In 2023, the diagnosed prevalence of schizophrenia in the US was approximately 767 thousand for males and 664 thousand for females. Projections indicate that these figures may vary over the forecast period (2024-2034).
• The leading Schizophrenia Companies such as Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others.
• Promising Schizophrenia Therapies such as AQW051 2 mg (single and multiple doses), Seroquel Sustained Release (SR), LY2140023, Moxifloxacin, Olanzapine Hydrochloride, and others

 

Gain a competitive edge in the Schizophrenia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Schizophrenia Treatment Drugs

 

Schizophrenia Epidemiology Segmentation in the 7MM

• Total Prevalent Cases
• Total Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases

 

Schizophrenia Market Insights

The mainstay of treatment includes medication and psychosocial therapy that can help manage the condition. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics, recommended as first-line treatment for schizophrenia, divided into first-generation (FGAs) and second-generation (SGAs) categories, are the primary pharmacological interventions. For some patient groups, treatment strategies include a combination of neuroleptics and antiepileptic. Both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are available for each generation.

 

Discover key developments and opportunities in the Schizophrenia Market. Click here to learn more from DelveInsight’s latest report @ Schizophrenia Market Size

 

Schizophrenia Treatment Market Landscape

Schizophrenia treatment revolves around medication management, the precise kind and dosage of medication used will depend on several variables, including the severity of the symptoms, the response to treatment, and any possible side effects and comorbidities. In addition to pharmacotherapy, psychosocial interventions play a crucial role in addressing functional impairments and promoting recovery. These may include cognitive-behavioral therapy to target cognitive distortions and enhance coping skills, social skills training to improve interpersonal relationships and community integration, and supported employment or education programs to facilitate vocational or academic pursuits. Thus, understanding that every person’s path to wellness is different highlights the significance of providing patient-centered, holistic care that honors each person’s particular experiences and goals.

 

Schizophrenia Marketed Drugs

• ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck
• UZEDY (risperidone): Teva Pharmaceuticals/MedinCell

 

Schizophrenia Emerging Drugs

• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
• Brilaroxazine (RP-5063): Reviva Pharmaceuticals

 

Download DelveInsight’s Schizophrenia Market report today and stay ahead in this rapidly evolving field. @ Schizophrenia Clinical Trials

 

Scope of the Schizophrenia Market Report

• Coverage- 7MM
• Schizophrenia Companies- Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others.
• Schizophrenia Therapies- AQW051 2 mg (single and multiple doses), Seroquel Sustained Release (SR), LY2140023, Moxifloxacin, Olanzapine Hydrochloride, and others
• Schizophrenia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

 

Download the report to understand which factors are driving Schizophrenia Market Trends @ Schizophrenia Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Schizophrenia Market Overview at a Glance

4. Methodology of Schizophrenia Epidemiology and Market

5. Executive Summary of Schizophrenia

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Schizophrenia: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/